‘Big Shoes To Fill’: US FDA Commissioner Hahn’s Baptism By Fire
Executive Summary
Every new FDA commissioner faces a challenge earning credibility with Congress and the public, but in the context of COVID-19, Stephen Hahn has a double challenge of a public health crisis – and the ongoing prominence of his predecessor at the agency.
You may also be interested in...
US FDA Commissioner Tries To Allay Concerns About Inspection Postponements
Screenings at ports of entry may be modified, but the drug supply remains safe and secure, Stephen Hahn tells House Committee, arguing that other tools will allow for continued facility policing during the coronavirus outbreak even if the absence of inspections.
Coronavirus Slams US Consumer Health Industry Event Schedules, FDA Meetings, Inspections
In addition to postponing NDAC meeting on food handler antiseptic drug products, FDA is suspending most inspections of foreign manufacturing facilities through April. Latest consumer health industry conferences cancelled or postponed are Consumer Healthcare Product Association and Informa Markets events.
Drug Shortage Legislation Gains Support As Coronavirus Threatens US Supplies
Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.